Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
about
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolutionSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementEngineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediationSex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: Insights into structural importance of residue 334A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisMetabolism and transport of oxazaphosphorines and the clinical implications.Utilisation of nanoparticle technology in cancer chemoresistance.The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes.Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.Resistance to chemotherapy in cancer: a complex and integrated cellular response.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Urological implications of cyclophosphamide and ifosfamide.Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal modelsImpact of glomerular kidney diseases on the clearance of drugs.Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.Psychophysiological stress: a significant parameter in drug pharmacokinetics.Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity.Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibUnderstanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS.Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.Hepatic Intra-arterial Delivery of a "Trojan-horses" Gene Therapy: A Pilot Study on Rabbit VX2 Hepatic Tumor Model.Bitargeting and ambushing nanotheranostics.Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide.Toward reduction in animal sacrifice for drugs: molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates.Klippel-Feil syndrome in a boy exposed inadvertently to cyclophosphamide during pregnancy: a case report.Cyclophosphamide-induced Down-Regulation of Uroplakin II in the Mouse Urinary Bladder Epithelium is Prevented by S-Allyl Cysteine.
P2860
Q21261309-581E99F4-38CB-44C0-8394-D0FA1EF104ECQ24294558-046110F4-EBD3-4948-BA0E-943342B67BE0Q26830695-A7579BEC-2743-46C7-9DD5-02FB05B333D3Q28749176-4D393348-542D-45B4-920F-A5EDC0A7CF11Q33384413-A6ADB18A-A469-4813-9B2A-D54D62A47BB2Q33410703-12FB7D86-7DA8-4482-ADD5-6AE79FDB751CQ33643424-B7322D39-ED8A-4585-A4CA-8759F4AC5F6CQ34010773-16D3C920-9ED0-4100-AE13-3E790E54E65AQ34457423-9D75B48E-6105-4B9A-BC39-8FC5443C44DBQ35651931-EC38F29F-A5CD-4777-AAF2-C9D8ECF8988DQ35745249-96C87A78-719A-4C2F-B945-4486319A177BQ36336024-F399FA16-CC3C-4503-8A97-C06A4945D42EQ36360811-760BFF4A-ACFC-4FB1-B6E4-04FCE7C48DF8Q36421258-EB00AE95-764E-4329-B372-8EB4BB7C809BQ36988710-C033E181-C53A-457E-9D1B-2E31956FF15AQ37037051-D9B6EAE0-C64F-4052-8A49-A4809BE66452Q37079652-D5FF763E-F0F9-4D93-A0AB-935061513849Q37079954-D39845C4-BAA6-4D5C-9552-7E33FE0F480AQ37264407-53A3170A-E3EA-44C3-A542-2BBF7173C609Q37386327-F1782531-9137-42C6-AD03-6C56783A4660Q37681776-D9188F03-67F5-42F7-8F5A-F0AA7563DA18Q37974647-ECB80658-D65F-4D64-8231-ED4F7F689E81Q38083753-97C5CAEA-257C-4580-9079-0B47EAFDA3B1Q38120048-7F221CBE-1CCB-48E9-8F9B-D338DBDD87E0Q38385149-83A86B24-B4C3-4198-80E0-6A2099FE2E9AQ38568650-3D0BA19A-CBA5-459D-AD67-86DE22C60689Q38660736-7FB9CFFA-5489-4BC8-8663-D963D608DA76Q39652106-8DC5F4B2-BFA9-4F69-9328-66EA706AADD4Q39823354-890ECC37-1D7F-4DA5-82EE-F7A5A52901DAQ40253486-C5016046-BF1C-41C7-AE61-D84D199233D6Q41830446-EE061279-FD46-4F42-AB40-200A06514082Q45084231-96B630DA-57FB-441B-BF26-CCE494CD2A57Q45873817-56B2F1AB-440D-4C82-A84D-10DEE88CB06BQ46223507-9D5A8F84-52E7-4076-9888-0AEC3E7ADB89Q46387102-91A47270-6B5F-4A8A-853A-1B40F33988D9Q51068004-56C6717D-345E-44C5-80ED-F02E3183E747Q51799336-77C49E30-65EF-4775-9443-C4C881AC8B1FQ53090495-C7CD9AF2-C8B0-4FFA-A6E3-58A4D1CD4088
P2860
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Activation of the anticancer p ...... with improved enzyme kinetics.
@en
Activation of the anticancer p ...... with improved enzyme kinetics.
@nl
type
label
Activation of the anticancer p ...... with improved enzyme kinetics.
@en
Activation of the anticancer p ...... with improved enzyme kinetics.
@nl
prefLabel
Activation of the anticancer p ...... with improved enzyme kinetics.
@en
Activation of the anticancer p ...... with improved enzyme kinetics.
@nl
P2093
P356
P1476
Activation of the anticancer p ...... with improved enzyme kinetics.
@en
P2093
Chong-Sheng Chen
Jack T Lin
James R Halpert
Kendrick A Goss
P304
P356
10.1124/MOL.65.5.1278
P577
2004-05-01T00:00:00Z